Nevro Corp (NVRO) Hits New 12-Month High at $81.93
Nevro Corp (NASDAQ:NVRO) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $81.93 and last traded at $80.75, with a volume of 48,490 shares traded. The stock had previously closed at $81.26.
Several equities research analysts have issued reports on NVRO shares. Leerink Swann restated a “buy” rating on shares of Nevro Corp in a research report on Monday, June 6th. Wells Fargo & Co. started coverage on Nevro Corp in a research report on Tuesday, July 12th. They set an “outperform” rating on the stock. Morgan Stanley restated a “buy” rating and set a $86.00 target price on shares of Nevro Corp in a research report on Wednesday, June 29th. Piper Jaffray Cos. assumed coverage on shares of Nevro Corp in a report on Friday, July 22nd. They issued an “overweight” rating and a $98.00 price target on the stock. Finally, William Blair assumed coverage on shares of Nevro Corp in a report on Tuesday, July 19th. They issued an “outperform” rating on the stock. Five research analysts have rated the stock with a buy rating, Nevro Corp presently has a consensus rating of “Buy” and an average price target of $92.00.
The firm has a 50-day moving average of $75.62 and a 200-day moving average of $65.38. The stock’s market cap is $2.30 billion.
In other news, VP Andre Walker sold 4,000 shares of Nevro Corp stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $73.50, for a total transaction of $294,000.00. Following the transaction, the vice president now owns 4,197 shares in the company, valued at approximately $308,479.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Doug Alleavitch sold 500 shares of Nevro Corp stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $72.00, for a total transaction of $36,000.00. Following the transaction, the vice president now owns 10,961 shares in the company, valued at approximately $789,192. The disclosure for this sale can be found here.
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.